Oncogenic viruses and hepatocellular carcinoma

Clin Liver Dis. 2015 May;19(2):341-60. doi: 10.1016/j.cld.2015.01.006. Epub 2015 Mar 7.

Abstract

About 80% of hepatocellular carcinoma (HCC) is caused by hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections especially in the setting of established cirrhosis or advanced fibrosis, making HCC prevention a major goal of antiviral therapy. HCC tumors are highly complex and heterogeneous resulting from the aberrant function of multiple molecular pathways. The roles of HCV or HBV in promoting HCC development are still either directly or indirectly are still speculative, but the evidence for both effects is compelling. In patients with chronic hepatitis viral infection, cirrhosis is not a prerequisite for tumorigenesis.

Keywords: Hepatitis B; Hepatitis C; Hepatocellular carcinoma; Oncogenic viruses.

Publication types

  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Carcinoma, Hepatocellular / prevention & control
  • Carcinoma, Hepatocellular / virology*
  • DNA, Viral*
  • Hepacivirus / genetics
  • Hepacivirus / physiology*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / physiology*
  • Hepatitis B, Chronic / complications*
  • Hepatitis B, Chronic / drug therapy
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / virology
  • Liver Neoplasms / prevention & control
  • Liver Neoplasms / virology*
  • Oncogenic Viruses
  • Virus Integration

Substances

  • Antiviral Agents
  • DNA, Viral